Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide...

5
Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January 1, 2010 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]

Transcript of Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide...

Page 1: Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January.

Platelet thrombin receptor antagonism and atherothrombosis

by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto

EHJVolume 31(1):17-28

January 1, 2010

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]

Page 2: Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January.

Sites of action of current and emerging antithrombotic drugs and antiplatelet agents.

Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]

Page 3: Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January.

Intracellular signalling pathways and phenotypic effects mediated by PAR-1 activation by thrombin in platelets.

Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]

Page 4: Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January.

Role of thrombin-mediated PAR-1 signalling in haemostasis vs. thrombosis: rationale for PAR-1 antagonist.38 In addition to activating PARs on platelets, thrombin facilitates fibrin formation and

protein C activation.

Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]

Page 5: Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January.

PAR-1 antagonists in clinical development.

Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]


Triglycerides and Risk for Atherothrombosis

Triglycerides and Risk for Atherothrombosis

International Expert Consensus on Switching Platelet P2Y ......Angiolillo et al 1956 November 14, 2017 Circulation. 2017;136:1955–1975. DOI: 10.1161/CIRCULATIONAHA.117.031164 Therefore,

International Expert Consensus on Switching Platelet P2Y ......Angiolillo et al 1956 November 14, 2017 Circulation. 2017;136:1955–1975. DOI: 10.1161/CIRCULATIONAHA.117.031164 Therefore,

ACTE D’INVESTIDURA DE DOCTOR HONORIS CAUSA...dos principals manuals sobre cardiologia: The Heart (El Cor), prèviament editat pel Dr. J. Willis Hurst i Atherothrombosis and Coronary

ACTE D’INVESTIDURA DE DOCTOR HONORIS CAUSA...dos principals manuals sobre cardiologia: The Heart (El Cor), prèviament editat pel Dr. J. Willis Hurst i Atherothrombosis and Coronary

Long-Term Management of Patients at Risk of Atherothrombosis.

Long-Term Management of Patients at Risk of Atherothrombosis.

Atherothrombosis Pathophysiology. What Is Atherothrombosis? The formation of a thrombus on an existing atherosclerotic plaque Atherothrombosis is a new.

Atherothrombosis Pathophysiology. What Is Atherothrombosis? The formation of a thrombus on an existing atherosclerotic plaque Atherothrombosis is a new.

Section 5.1 Pharmacodynamic properties · Section 5.1: Pharmacodynamic properties The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial

Section 5.1 Pharmacodynamic properties · Section 5.1: Pharmacodynamic properties The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial

LA PIÙ GRANDE OPERA ITALIANA IN UN UNICO IMPERDIBILE ... · la piÙ grande opera italiana in un unico imperdibile spettacolo con: antonello angiolillo, myriam somma, noemi bordi,

LA PIÙ GRANDE OPERA ITALIANA IN UN UNICO IMPERDIBILE ... · la piÙ grande opera italiana in un unico imperdibile spettacolo con: antonello angiolillo, myriam somma, noemi bordi,

Cardiovascular Ischemic Event Rates in Outpatients With Symptomatic Atherothrombosis or Risk Factors in the United States: Insights From the REACH Registry.

Cardiovascular Ischemic Event Rates in Outpatients With Symptomatic Atherothrombosis or Risk Factors in the United States: Insights From the REACH Registry.

UF Diabetes Institute · heart disease, so that they reduce their risk of having future heart attacks or need for heart surgeries? What if… Dominick J. Angiolillo, M.D., PhD, medical

UF Diabetes Institute · heart disease, so that they reduce their risk of having future heart attacks or need for heart surgeries? What if… Dominick J. Angiolillo, M.D., PhD, medical

LEADING THE WAY · Asfia Ali Murray S. Allen The Tom & Janet Alton Family Fund Tony & Suzy Anderson Alexandru Andriuca Wendy Andrushko Julie Angiolillo Allyson Angus Joseph Arbour

LEADING THE WAY · Asfia Ali Murray S. Allen The Tom & Janet Alton Family Fund Tony & Suzy Anderson Alexandru Andriuca Wendy Andrushko Julie Angiolillo Allyson Angus Joseph Arbour

Reestablishment of Ventricular Pumping Efficiency and ... · Luis Jesu´s Jime´nez-Borreguero2,4*, Nadia Mercader1* 1. Department of Cardiovascular Development and Repair, Atherothrombosis

Reestablishment of Ventricular Pumping Efficiency and ... · Luis Jesu´s Jime´nez-Borreguero2,4*, Nadia Mercader1* 1. Department of Cardiovascular Development and Repair, Atherothrombosis

Vitamin в : Pyridoxine, Pyridoxal and Pyridoxaminebcpw.bg.pw.edu.pl/Content/3747/researcg_1949_s507.pdf · eHj,0,N.HCl. It was certainly pyridoxine, although Ohdakc did not recognize

Vitamin в : Pyridoxine, Pyridoxal and Pyridoxaminebcpw.bg.pw.edu.pl/Content/3747/researcg_1949_s507.pdf · eHj,0,N.HCl. It was certainly pyridoxine, although Ohdakc did not recognize

NEPCon Evaluation of EHJ Energi A/S Compliance with the SBP … · 2020-03-31 · Focusing on sustainable sourcing solutions NEPCon Evaluation of EHJ Energi A/S: Public Summary Report,

NEPCon Evaluation of EHJ Energi A/S Compliance with the SBP … · 2020-03-31 · Focusing on sustainable sourcing solutions NEPCon Evaluation of EHJ Energi A/S: Public Summary Report,

mendekandidaathoOrdedathjja琯ewezenwas’zuch ehj】engmg spelling 02...‘6 mendekandidaathoOrdedathjja琯ewezenwas’zuch ehj】engmg

mendekandidaathoOrdedathjja琯ewezenwas’zuch ehj】engmg spelling 02...‘6 mendekandidaathoOrdedathjja琯ewezenwas’zuch ehj】engmg

Four Roads to Richmond - Gerald Toddtodd.mainecav.org/lfm/chancellorsville_four_roads_to...Four Roads to Richmond From the Avalon Hill General, volume 12, number 6, by Joseph A. Angiolillo

Four Roads to Richmond - Gerald Toddtodd.mainecav.org/lfm/chancellorsville_four_roads_to...Four Roads to Richmond From the Avalon Hill General, volume 12, number 6, by Joseph A. Angiolillo

Pathology and Pathophysiology of Atherothrombosis: …In 1856, Rudolf Virchow published Cellular pathology based on macroscopic and microscopic observation of diseases, and described

Pathology and Pathophysiology of Atherothrombosis: …In 1856, Rudolf Virchow published Cellular pathology based on macroscopic and microscopic observation of diseases, and described

Heart Failure Guidelines 2016 - swisscardio.ch · Heart Failure Guidelines EHJ / EJHF 201627.06.2016 11 / PATIENT WITH SYMPTOMATIC HFrEF Heart Failure Guidelines EHJ / EJHF 2016

Heart Failure Guidelines 2016 - swisscardio.ch · Heart Failure Guidelines EHJ / EJHF 201627.06.2016 11 / PATIENT WITH SYMPTOMATIC HFrEF Heart Failure Guidelines EHJ / EJHF 2016

Inflammation and Atherothrombosis: An Update on Trials ...cme.baptisthealth.net/cvdprevention/documents/2015/2015 presentations/ridker...1 Inflammation and Atherothrombosis: An Update

Inflammation and Atherothrombosis: An Update on Trials ...cme.baptisthealth.net/cvdprevention/documents/2015/2015 presentations/ridker...1 Inflammation and Atherothrombosis: An Update

Pathology and Pathophysiology of Atherothrombosis: Virchow ...cdn.intechopen.com/pdfs/35724.pdf · Pathology and Pathophysiology of Atherothrombosis: Virchow’s Triad Revisited 3

Pathology and Pathophysiology of Atherothrombosis: Virchow ...cdn.intechopen.com/pdfs/35724.pdf · Pathology and Pathophysiology of Atherothrombosis: Virchow’s Triad Revisited 3

Anticoagulant and Anti-Platelet Medications · 2020. 12. 14. · Thrombin and Platelet Thrombus Formation Franchi F, Rollini F, Park Y, Angiolillo DJ. Platelet thrombin receptor antagonism

Anticoagulant and Anti-Platelet Medications · 2020. 12. 14. · Thrombin and Platelet Thrombus Formation Franchi F, Rollini F, Park Y, Angiolillo DJ. Platelet thrombin receptor antagonism